Enanta Pharmaceuticals (ENTA) Stock Forecast & Price Target

Enanta Pharma is supported by a clearer regulatory path for zelicapavir in RSV, as FDA alignment on a single Phase 2b/3 study reduces development uncertainty and preserves a route to registration while keeping hospitalization reduction and symptom resolution as meaningful differentiators. The RSV opportunity appears substantial, with management citing roughly 2.7 million potential patients across high-risk adults and pediatrics and a market opportunity approaching $2B to $2.5B annually, while the planned pediatric Phase 2b study in 3Q26 and adult initiation in 4Q26 add multiple catalysts. The company also has a compelling next-stage immunology asset in EDP-978, where highly selective oral KIT inhibition, potential once-daily dosing, and the prospect of meaningful tryptase reductions could create upside if 4Q26 Phase 1 data confirm target engagement and clean tolerability.

Enanta Pharma is facing a weak fundamental setup because much of its pipeline value remains highly uncertain, with only a 50% probability of success assigned to Zelicapavir in RSV and conservative value placed on the rest of the portfolio. The cited 4Q26 Phase 1 readout for EDP-978 is viewed as carrying little value in the stock today, while the modeled late 2029 or early 2030 launch for Zelicapavir pushes meaningful cash generation far out and depends on clinical, regulatory, commercial, and IP execution. Even with a 13.7% WACC and a 9.5x exit multiple applied to 2034 estimates, the reliance on future royalties and a narrow set of assets leaves the shares exposed to substantial downside if development disappoints.